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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
Alzheimer's Disease (AD) is a debilitating human 
neurodegenerative condition, the risk of which increases 
steadily with age. AD is characterized by a progressive 
neurological deterioration and corresponding loss of mental 
faculties. Eventually an AD patient becomes unable to care 
for him/herself and requires full-time assistance. The 
disease is presently terminal in all cases, and represents a 
forthcoming public health crisis as human lifespans increase 
and the large post-World War II generation enters the age 
group at highest risk for the disease. 
Current therapies for AD are extremely limited, and 
provide only temporary, symptomatic relief. The handful of AD 
drugs on the market can slow the progression of the disease 
for a few months at best, but soon lose their efficacy 
(Eastley et al., 2001). At present, no therapy exists which 
can halt or reverse the CNS deterioration that is 
characteristic of the disease. 
Neural stern cells have recently generated much excitement 
in the medical community for their potential use as a source 
of new neurons to replace those lost to neurodegenerative 
diseases. However, the potential of these cells is largely 
still untapped, owing mainly to our limited understanding of 
their basic biology. Here, we investigate the biology of 
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neural stem cells in an in vitro model of AD to assess their 
potential for therapeutic use. 
Thesis organization 
The following thesis is composed of three main sections. 
The first section (Chapter 1) includes a general introduction 
and a literature review on Alzheimer's Disease, Beta-Amyloid 
peptide, stem and progenitor cells, and transplantation 
therapy. 
Chapter 2: Amyloid-Beta Peptide Affects Viability and 
Differentiation of Embryonic and Adult Rat Hippocampal 
Progenitor Cells, James N. Eucher, Etsuro Uemura, Donald S. 
Sakaguchi, and M. Heather West Greenlee, is a manuscript which 
will be submitted for publication in Experimental Neurology. 
Eucher was the major contributor to the investigation, and 
author of the manuscript, under the supervision of Greenlee, 
Uemura, and Sakaguchi. 
Chapter 3 is a general discussion of the results 
presented in Chapter 2, as well as discussion of results from 
additional, unpublished experiments. It also includes 
direction of future research. The appendix contains the 
unpublished results referred to in Chapter 3. 
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Literature Review 
Alzheimer's Disease 
Alzheimer's Disease (AD) was first recognized as a 
distinct clinical entity in the early 20th century. An autopsy 
was conducted on a 51-year-old female who had exhibited a 
variety of symptoms, including depression, hallucinations, and 
general cognitive impairment. The physician examining the 
brain (Dr. Alois Alzheimer, after whom the disease was later 
named) noted gross pathological changes including thinning of 
gyri and widening of sulci in the cerebral cortex, as well as 
an enlargement of the cerebral ventricles. On microscopic 
examination, extensive formations of dense extracellular 
plaques were noted, as were intracellular fibrillary tangles 
within many neurons (Alzheimer, 1907). 
Over the next several decades, further characterization 
of the disease was accomplished. The extracellular plaques 
that Alzheimer had observed were determined to be composed 
primarily of a small peptide of consistent sequence known as 
amyloid. The intracellular neurofibrillary tangles (NFTs) 
were determined to be repeats of a hyperphosphorylated 
cytoskeletal component called Tau. Neurons containing NFTs or 
located near amyloid plaques tend to die, and this neuronal 
loss seems to be concentrated in specific areas of the brain 
including the hippocampus, frontal cortex, and limbic system. 
Neuronal death in these areas leads to specific functional 
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deficits characteristic of AD, such as difficulty in 
reasoning, emotional instability, and memory impairment. 
A key molecular player in AD was identified as a small 
protein of about 700 amino acids called Arnyloid Precursor 
Protein (APP). This protein is widely expressed throughout 
the body in many tissue types, and is highly expressed in the 
central nervous system (CNS). Despite much study, the exact 
function of APP in normal physiology is not clear. APP 
knockout animals survive and are generally healthy, if less 
active than wild-type animals (Zheng et al. 1995). 
Within the benign APP protein, a potential threat 
resides. A short component sequence of APP, called arnyloid, 
is an oligopeptide of 39-43 residues in size, and is located 
near the C terminus of APP (Mattson et al., 1993). If 
liberated, amyloid is thought to be involved in a plethora of 
toxic effects on neurons (discussed in next section). 
In the human brain, APP is initially cleaved by one of 
two proteases. The first, dubbed a-secretase, cleaves APP in 
the middle of the amyloid segment (Parvathy et al., 1998), 
precluding the liberation of the toxic amyloid fragment. 
Alternatively, cleavage by B-secretase cuts at a site closer 
to the N terminus of APP, lopping off a fragment of 
approximately 100 AA that contains the amyloid sequence 
(Vassar, 2004). 
For some time, the enzyme responsible for paring down the 
100 AA fragment into the 39-43 AA fragment known as amyloid 
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was not identified. Recent work by many groups, however, has 
established the identity of a polysubunit enzyme known as y-
secretase (for review see Kimberly and Wolfe, 2003). Cleavage 
by y-secretase produces two prominent forms of amyloid, known 
as amyloid 1-40 or 1-42, which are, respectively, 40 or 42 AA 
in length (Wolfe et al., 1999). These monomers tend to 
aggregate together, assuming a fl-pleated sheet conformation. 
An aggregation of many amyloid monomers in this conformation 
is known as amyloid-beta (AB). 
Although there is not complete consensus within the 
scientific community that AB is the primary causal agent of 
AD, it is clear that a process of neuroinflammation is a major 
contributor to neuronal loss. Studies have shown that the 
presence of a wide variety of molecules, including 
interleukins, tumor necrosis factor, other cytokines, and AB 
itself, can cause an increase in inflammation in the brain, 
and subsequent neuronal damage/death (for review see Wang and 
Shuaib, 2002, and Eikelenbloom et al., 2002). Mice transgenic 
for a mutant APP gene (which leads to increased AB production) 
show higher levels of the inflammatory mediator p38 MAP-kinase 
in their microglia, and increased microglial activation; when 
subjected to focal brain ischemia, they show significantly 
more neuronal damage then do controls, suggesting that the 
neuroinflammatory process renders neurons less resistant to 
additional insults (Koistinaho et al., 2002). In another 
study, primary cultures of hippocampal neurons were engineered 
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to express mutations in presenilin-1 (one of the components of 
the y-secretase) that lead to increased AJ3 liberation. 
Addition of a molecule that damages DNA, etoposide, caused a 
more vigorous inflammatory response, and more cellular damage, 
than was observed in controls (Chan et al., 2002). 
Several studies have attempted to determine the 
distribution of various proteins that are thought to be 
involved in the pathology of Alzheimer's Disease. Konishi et 
al., 2003 utilized immunochemical techniques to show that 
frame-shift mutant forms of APP were present in the brains of 
AD patients, as well as those patients who at time of death 
did not have AD but showed more AD-like neuropathology than 
controls. This study also noted that complement proteins were 
seen only in diagnosed AD brains, suggesting that inflammatory 
events such as complement activation may not be observed when 
the disease is still at subclinical levels. Yan et al., 2004 
made use of y-secretase inhibitors to map the distribution of 
y-secretase in adult rat brain. Most y-secretase was localized 
to the forebrain, cerebellum, and brainstem. Of these 
locations, only the forebrain is typically associated with 
much AD pathology - but interestingly, within these areas, y-
secretase seemed to be present at the highest levels in areas 
of most neuronal terminals - and by extension, in areas of 
most synaptic plasticity. 
Imaging technologies that permit in vivo examination of 
the AD brain, allowing clinicians and researchers to observe 
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the progress of the disease, are still at a relatively 
primitive stage. However, some findings of interest have 
already been made. A study using MRI and labeled brain 
metabolites such as choline found that metabolite levels were 
lower in the left temporal lobe in patients with diagnosed AD, 
as well as patients with mild cognitive impairment (not enough 
to make a diagnosis of AD) relative to the levels in healthy 
controls (Chantal et al., 2004). MRI and 3-D cortical mapping 
has been used to visualize the loss of gray matter in AD 
patients. When compared to healthy age-matched controls, AD 
patients began with less gray matter volume, and lost it at a 
faster rate, than did their control counterparts. Gray matter 
loss was greatest in the areas typically associated with worst 
AD pathology, and decreased volume of gray matter correlated 
very strongly with worsening cognitive status (Thompson et 
al., 2003) . 
Amyloid-Beta 
Several decades of study have resulted in a general 
consensus among AD researchers that AB is a major contributor 
to neurodegeneration in the Alzheimer's brain. AD is a 
sufficientl y complex disease that its actual etiology is 
likely to be multifactorial; thus one can examine the role of 
AB in deve l opment of AD pathology without closing a door to 
the additional contribution of other molecules such as Tau. 
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The amino acid sequence of AJ3 is known and is consistent 
within a given species. In the human, AJ3 1-40 and 1-42 are 
most prevalent, with 1-42 generally considered the more toxic 
form. As the disease progresses, the ratio of AJ3 1-40 to AJ3 
1-42 typically shifts to favor the latter form (Kienlen-
Campard et al., 2002). The N-terminus of the peptide is 
hydrophilic, while the C-terminus is hydrophobic. The region 
26-29 is a B-turn and is necessary for amyloid monomers to 
aggregate. The 25-35 region of AJ3 is believed to be the 
neurotoxic site - amyloid segments of various lengths and 
configurations are not toxic if the 25-35 region is missing or 
incomplete; however the rest of the protein can add to its 
toxicity - for example, full length AJ3 1-42 is more toxic than 
AJ3 25-35 (Pike et al., 1995). 
A number of reviews have examined the various mechanisms 
proposed for AJ3 toxicity over the past decade. Mattson, 1997 
focuses on the biochemistry of APP, concluding that cleavage 
by the a-secretase generates beneficial products, unlike~ and 
y-secretase cleavage which liberates AB. Harkany, et al., 
2000 explore AJ3 toxicity in terms of what has been learned 
from various pharmacological studies, suggesting that AJ3 may 
act directly on the NMDA receptor. A fairly recent review, 
written since the identification of the y-secretase, is Atwood 
et al. (2003), which points out that AJ3 may even be 
neurotrophic in certain situations, but that its oxidative 
properties are largely deleterious to the cell. 
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A number of toxic activities have been attributed to AB 
in recent years. One theory is that AB subjects the brain to 
a level of oxidative stress that exceeds its antioxidant 
capacity (Mattson, 1997). Most formulations of this theory 
include the idea that the oxidative damage affects not only 
neurons directly, but also indirectly by causing astrocytic 
dysfunction - some argue that M's indirect actions, via 
astrocytes, are ultimately the more damaging than its direct 
effects on neurons (Paradisi, et al, 2004). AB 1-42 and 25-35 
have been shown to decrease levels of the antioxidant 
glutathione in astrocytes, which are normally responsible for 
neutralizing reactive oxygen species (ROS) in the brain 
(Abramov et al., 2003). Indeed, AB has been shown to increase 
production of ROS in astrocytes, through activation of NADPH 
oxidase, wh ich in turn makes neurons in the vicinity more 
vulnerable to ROS attack (Abramov et al., 2004). Wyss-Coray 
et al., 2003 showed that cultured astrocytes migrated toward 
AB plaques in brain sections, and reduced the AB load after 
arriving in areas with dense AB accumulation. However, 
examination of post-mortem brains from AD victims has 
demonstrated that many small amyloid plaques are built around 
astrocytes containing AB 1-42 as well as neuron-specific 
proteins like ChAT and nAChR, suggesting that while astrocytes 
may clean up destroyed neurons and synapses, the astrocytes 
eventually become overburdened, exceed their phagocytic 
capacity, lyse, and die, adding to the overall plaque load in 
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the brain (Nagele et al., 2003). Paradisi, et al., 2004, 
report that neurons exposed to AB for several days do better 
than controls when healthy astrocytes are then added in 
culture. Conversely, neurons actually sustained more damage 
when they were grown in co-culture with astrocytes, and both 
cell types were exposed to AB from the beginning - the 
implication being that healthy astrocytes can aid neurons, but 
unhealthy astrocytes may contribute to the pathology. 
Several studies have shown direct effects on neurons by 
AB. Treatment of neurons in primary culture with AB 1-42 or 
25-35 inhibits fast axonal transport within the cell (Hiruma 
et al., 2003). Treatment of primary culture neurons with AB 
25-35 has also been shown to inhibit glucose uptake, possibly 
via a mechanism involving inhibition of GLUT3 vesicle fusion 
with the neuronal plasma membrane (Uemura and Greenlee, 2001). 
Neurons treated with AB 1-42 show an inability to bind 
cholesterol, which would in turn result in a neuron's 
inability to repair or remodel its cell membrane (Yao and 
Papadopoulos, 2002). 
In addition to deleterious effects on neurons and 
astrocytes, Xu et al., 2001 were the first to demonstrate that 
AB treatment caused decreased viability and increased cell 
death of oligodendrocytes in primary culture. Myelin loss 
from the brain's white matter is observed in a significant 
proportion of brains from AD victims (Tian et al., 2004). 
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Much of the neuronal death that occurs in Alzheimer's 
Disease is thought to proceed via apoptosis. Several proteins 
that are players in the apoptotic cascade have been discovered 
to be significantly upregulated in the frontal cortex of 
patients with AD relative to controls (Engidawork et al., 
2001). Mattson, 2000, breaks the apoptosis pathway down into 
three distinct steps: initiation of apoptosis by influences 
such as oxidative stress, excitotoxicity, or growth factor 
deprivation; mitochondrial dysfunction leading to caspase 
activation; and enzyme activity which results in membrane 
blebbing, nuclear fragmentation, and death. Several studies 
have shown that AB activates caspase-3 in cultured neurons or 
AD brain sections, and that activation of neuronal caspase-3 
is a near-guarantee that a cell will undergo apoptotic death 
(Stadelmann et al. 1999; Harada et al. 1999; Uetsuki et al. 
1999; Ioudina and Uemura, 2003). Uetsuki et al. 1999 also 
reported that inhibition of caspase-3 restored cell survival 
to nearly 100%. Some debate exists as to whether caspase-3 is 
the most important therapeutic target in relation to AB 
toxicity. Troy et al. 2000 argue that caspase-2 is more 
important than is caspase-3 - using inhibitors to caspases 1, 
2, or 3, they found that inhibiting caspase-2 returned cell 
survival to near 100%, whereas inhibiting the other two had 
minimal effect on survival. Another study drew yet another 
conclusion, finding that selectively inhibiting any one of 
caspases 2, 3, or 6 was significantly neuroprotective. 
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Another layer of complexity is added by the interaction 
between caspases and calpains (calcium-dependent protein 
kinases), which are thought to be involved in both apoptotic 
and necrotic cell death (Denecker et al., 2001). Neumar et 
al., 2003, report that when calpains were inhibited with 
calpastatin in human neuroblastoma cells, and the pro-
apoptotic molecule staurosporine was then added, caspase 
activity spiked sharply, and the caspases degraded 
calpastatin. Subsequently, calpain activity also rose, and 
apoptosis increased substantially. Taken together, the results 
of these studies on A13 and cell survival indicate that any 
therapeutic approach aimed solely at a single one or single 
group of pro-apoptotic enzymes such as caspases or calpains 
will likely be insufficient. 
Within the last five years, the idea of recruiting the 
immune system to clear AJ3 from the brain has received much 
attention (Weiner and Selkoe, 2002). Immunization experiments 
in rodents showed that immunization with AJ3 led to a reduction 
in AJ3 deposits in the brain (Schenk et al., 1999; Weiner et 
al., 2000). However, a human trial, in which AD patients were 
immunized with synthetic A13 1-42 and the adjuvant QS21, was 
discontinued in Phase II clinical trials when several patients 
experienced a severe aseptic meningoencephalitis (review by 
Broytman and Malter, 2002). 
A fundamental, and unanswered, question regarding AJ3 is 
its effective concentration in vivo. While several 
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researchers have offered estimates ranging from the nanornolar 
(Abe and Kimura, 1996; Kato et al., 1997) to rnicrornolar (Behl 
et al., 1994; Dore et al., 1997) concentrations, these 
represent an "educated guess" as no method presently exists 
for quantifying AJ3 load in the living brain. A recent study 
identified a series of styrylbenzoxazole derivatives that bind 
AJ3 with high affinity, easily cross the blood-brain barrier, 
and do not cause side effects in rodents (Okamura et al. 
2004). These compounds may be useful in conjunction with PET 
or CT imaging to image AJ3 plaques (although not quantify their 
concentrations) in vivo. 
Stem Cells and Transplantation Therapy 
Because the neurological deficits in AD are ultimately 
due to damage and death of neurons (and perhaps glia) in 
affected regions, stern cell transplantation therapy has been 
proposed as a possible therapeutic approach (Suguya, 2003). 
The general concept behind transplantation therapy is to 
introduce neural stern cells into the brain of an AD patient. 
These stern cells may either respond to cues from the damaged 
area, or be pre-treated prior to transplantation, such that 
they differentiate into new cells that can replace those lost 
to the disease, ameliorating the functional deficits that had 
been present. 
To some extent, the concept of a "stern cell" is intuitive 
to the anatomy of a complex multicellular animal, when one 
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considers that all the billions of cells comprising an adult 
must originate from a single zygote. Current definitions of a 
stem cell all include two main characteristics. The cell must 
first be multipotent - have the capacity to give rise to 
several kinds of differentiated cells; and second, stem cells 
must be self-renewing - capable of replicating more 
undifferentiated cells identical to itself (Gage, 2000). 
The first cells of an organism that meet the 
aforementioned criteria, and thus can be considered true stem 
cells, are those of the inner cell mass of the blastocyst -
the so-called "embryonic stem cells". These cells have the 
capacity for self-renewal - placed in appropriate tissue 
culture conditions, they will freely replicate themselves. 
They also have a very broad capacity for differentiation - a 
single embryonic stem cell (ESC), depending on the signals it 
receives, should be capable of differentiation into nearly any 
cell type in the body (Gage, 2000). 
A cell's differentiation ability becomes noticeably less 
broad at the level of the multipotent stem cell. Multipotent 
stem cells can self-renew, and generally have the ability to 
form all the cell types in a given tissue. However, their 
self-renewal capacity may be limited - after a certain number 
of divisions, they may enter a senescent state and be capable 
of no further divisions. They are usually referred to in 
reference to the tissue type they give rise to (ex: neural 
stem cells, hematopoietic stem cells, etc). Multipotent stem 
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cells have long been recognized in the embryo or fetus, and in 
certain adult tissues that frequently replace their cells, 
such as epithelium. However, until recently, adult stem cells 
had not been identified in tissues with minimal adult 
regenerative capacity, such as those of the nervous system. 
Only within the last decade have neural stem cells been 
positively identified in the adult animal (Lois and Alvarez-
Buylla, 1993; Kuhn et al., 1996; Palmer et al., 1997). 
For most stem-like cells, there is some measure of 
ambiguity as to when they leave the category of multipotent 
stem cells, and enter the next - that of progenitor cells. 
Typically, progenitor cells are defined as cells which can 
give rise to all the cell types in a particular structure or 
region (ex: hippocampal progenitor cells, retinal progenitor 
cells, etc). Significantly, progenitor cells may exhibit a 
lower limit on their self-renewal capacity compared to 
multipotent stem cells. They also may be more restricted in 
terms of the cell types they can generate for example, a 
h~ppocampal progenitor cell may not be able to give rise to 
neuronal types not seen in the hippocampus, such as Purkinje 
cells. 
While a progenitor cell can give rise to all the cell 
types in a particular structure, a committed progenitor cell 
is limited to giving rise only to the cells of a distinct 
developmental lineage withi? that structure (ex: a glial 
precursor cell can give rise to astrocytes and 
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oligodendrocytes but not neurons). Committed progenitors are 
sometimes limited in the number of divisions they can undergo; 
at this point the cells may also begin expressing molecular 
markers, and/or showing morphological features, characteristic 
of the differentiated cell types they can generate. Important 
to note is that while committed progenitor cells may share 
some phenotypic characteristics with the mature cell types 
they can generate, they lack the functional characteristics of 
those cells - for example, a neuronal progenitor cell may look 
something like a neuron, but it is not capable of producing 
action potentials (Zhang, 2001). 
At the opposite end of the spectrum from the ESC, we find 
the fully differentiated cell. These are functional cells 
that no longer have any degree of multipotency - they are 
fully committed to a specific cell type, and possess all the 
appropriate phenotypic and functional characteristics. In the 
central nervous system, the three primary types of 
differentiated cells are neurons, astrocytes, and 
oligodendrocytes. 
Although adult neurogenesis is thought to be limited to 
two regions, the hippocampal dentate gyrus and the 
subventricular zone beneath the lateral ventricles (van der 
Kooy, 2002), neural stem cells have been isolated from both 
neurogenic and non-neurogenic regions of the nervous system. 
Areas from which NSCs have been isolated include hippocampus 
(Palmer et al. 1997), white matter (Nunes et al. 2003), 
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olfactory bulb (Pagano et al. 2000), spinal cord (Rao et al. 
1998), and hypothalamus (Markakis et al. 2004). 
Several recent studies have explored the control of 
proliferation and differentiation of neural stem cells. The 
Wingless (Wnt) signaling pathway appears to be involved in the 
switch from proliferation to differentiation. Pharmacological 
stimulation of the Wnt pathway causes cells to remain 
proliferative; conversely, inhibition of Wnt gene products 
induces cells to stop proliferating and begin differentiation 
(Sato et al . , 2004). The gene Notchl has also been linked to 
control of proliferation. Attenuation of Notch signaling in 
neural stem cells increased differentiation of both neurons 
and glia, while increased activation of Notchl led to more 
proliferation and less differentiation (Hitoshi et al., 2002). 
The protein Sonic hedgehog (Shh) causes increases in both 
proliferation and differentiation of all lineages in neural 
stem cells (Lai et al. 2003). Son et al., 2001 report that 
dexamethasone, a synthetic glucocorticoid, has an inhibitory 
effect on the differentiation of hippocampal progenitor cells, 
and that this effect could be blocked by application of RU486, 
a glucocorticoid receptor antagonist. Chronic high levels of 
interleukin-6 (IL-6, a proinflammatory molecule) have been 
shown to significantly reduce proliferation, differentiation, 
and survival of neural progenitor cells in the adult mouse, 
which may help explain why diseases with substantial neuronal 
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loss often include an inflammatory component (Vallieres et 
al., 2002). 
Several proteins have been identified which seem to bias 
neural stem cells toward the adoption of a particular lineage 
fate. Bone morphogenic proteins were identified over a decade 
ago as important players in embryonic development, and have 
been shown to direct NSCs to adopt a predominantly glial fate 
(Shah et al., 1996). Ueki et al 2003 identified a protein, 
which they named Neurogenesin-1, that exerted antagonistic 
effects on the BMPs and thereby enhanced neurogenesis. 
Turnley et al 2002 show that knockouts of the protein SOCS2 
(suppressor of cytokine signaling 2) produce substantially 
more glia than wild-types, while overexpression of SOCS2 
yields more neurons than normal. Amouroux et al., 2000, found 
that NSCs cultured in the presence of the neural cell adhesion 
molecule (NCAM) tended to differentiate along a neuronal 
lineage. 
Progenitor cells of the hippocampus have received 
significant attention in the literature over the last several 
years. The hippocampus is a particularly intriguing site for 
progenitor cell isolation for two reasons. First, a number of 
factors are known to be particularly injurious to the 
hippocampus in disease states, such as ischemia, oxidative 
stress, and high levels of excitatory neurotransmitters 
(Yagita et al., 2001; Dash et al., 2001). Second, the dentate 
19 
gyrus of the hippocampus represents one of only two known 
regions of adult neurogenesis (Gage, 2000). 
The first detailed isolation and characterization of 
neural progenitor cells from the hippocampus was done by 
Palmer, et al., 1997. They isolated EGF and bFGF-responsive 
cells from the hippocampus of adult rats. In culture, these 
cells (termed AHPCs - adult hippocampal progenitor cells) 
showed the ability to self-renew without chromosomal or other 
abnormalities for at least 35 population doublings. The cells 
could be induced to differentiate by withdrawal of growth 
factors, and generated neurons, astrocytes, and 
oligodendrocytes under in vitro differentiation conditions. 
Effect of various growth factors on HPCs was one of the 
first, and still major, topics of interest for these cells. 
Kuhn et al., 1997 investigated the effects of EGF and bFGF on 
neural progenitors of the hippocampus and subventricular zone 
in vivo. Intracerebroventricular infusion of EGF and bFGF 
suggested that neither affected in vivo proliferation of HPCs, 
but that EGF increased gliogenesis and decreased neurogenesis. 
Another intriguing finding was that progenitor cells isolated 
from non-neurogenic regions of the adult CNS, such as cortex 
and optic nerve, will generate neurons in vitro after exposure 
to bFGF, just as HPCs do (Palmer, 1999). The implication is 
that fully capable neural progenitor cells may exist 
throughout the adult CNS, but in most regions they produce 
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only glia because they are lacking certain environmental 
signals to encourage or permit neurogenesis. 
Shetty and Turner, 1998 investigated the effects of 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3), and glial-derived neurotrophic factor (GDNF) on HPCs in 
culture. Cells treated with BDNF showed increased survival 
and differentiation along a neuronal lineage; NT-3 and GDNF 
showed no effect. 
Another growth factor thought to affect HPCs is insulin-
like growth factor 1 (IGF-1). Aberg et al. 2000 have 
demonstrated that peripheral (subcutaneous) administration of 
IGF-1 to adult rats leads to increased progenitor cell 
proliferation and neurogenesis in the hippocampus, with no 
effects on gliogenesis. A later in vitro study by this group 
concluded that the IGF-1 effects are mediated by the mitogen-
activated protein kinase (MAPK) pathway. This study also 
demonstrated an additive effect of bFGF and IGF-1 in 
stimulating the proliferation of the HPCs. Significantly, 
bFGF treatment increased the expression of the IGF-1 receptor, 
suggesting a mechanism for their synergistic action (Aberg et 
al. 2003). 
Toda et al., 2003 used a variety of cDNA and RNA 
screening methods to identify a survival factor secreted by 
adult HPCs themselves. Stem cell-derived neural 
stem/progenitor cell supporting factor (SDNSF) is expressed in 
the rat hippocampus throughout life, and is upregulated in 
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response to ischemic injury. HPCs treated with SDNSF after 
withdrawal of bFGF maintained their self-renewal potential. 
Based on their experiments, the authors suggest that SDNSF 
acts in an autocrine and/or paracrine manner. Interestingly, 
SDNSF was not detected outside of the hippocampus, and was 
conspicuously absent from the subventricular zone, another 
known area of adult neurogenesis. 
The AHPC line characterized by Palmer, 1997, has been of 
some interest for use in transplantation to the retina. 
Takahashi et al., 1998 were the first to do so, grafting AHPCs 
into the vitreous of newborn and adult rats. The transplanted 
cells integrated well, particularly in the newborn eyes. Many 
cells took on morphologies consistent with retinal cell types 
such as Muller glia, bipolar cells, and photoreceptors, 
although the cells did not express all the immunological 
markers consistent with these cell types. Young et al. 2000 
injected GFP-transfected AHPCs into the vitreous of RCS rats 
(a particular strain frequently employed as a model of retinal 
degeneration). AHPCs survived in the retina for as long as 18 
weeks. The cells' progeny could be identified by GFP 
expression; progeny expressed a number of mature neuronal 
markers and appeared to migrate to appropriate layers within 
the retina. A later study by Suzuki et al. 2003 injected BDNF 
along with the AHPCs; when BDNF was included as a component of 
the cell injections, more AHPCs were found to express neuronal 
markers (such as MAP2) and fewer were seen to express neural 
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stem cell markers (such as Nestin) when examined several weeks 
after transplantation. 
Seaberg and van der Kooy, 2002, reported that the stem-
like cells found in the dentate gyrus were neuronally-
restricted progenitors rather than true neural stem cells. 
They used microdissection techniques to remove very small 
samples of tissue from hippocampal DG and subventricular zone. 
After culturing the cells and processing them with 
immunocytochemistry, they concluded that the cells isolated 
from the DG were not multipotent - they could form neurons, 
but not glia. Conversely, they argued that the cells of the 
SVZ exhibited true multipotency; thus the SVZ contained true 
neural stem cells while the DG did not. Seaberg and van der 
Kooy additionally believed that the multipotent AHPCs were not 
true DG residents but instead were an artifact of SVZ cells 
contaminating samples obtained from the DG. Aberg et al., 
2003 took issue with these claims, responding that the 
dissection technique used by Seaberg and van der Kooy was also 
flawed, allowing DG contamination of their SVZ section. They 
also noted that Alvarez-Buylla and others have used the van 
der Kooy dissection technique to successfully isolate 
multipotent stem cells from the DG (unpublished data). This 
dispute has not yet been fully resolved, but to date 
additional studies supporting the viewpoint of Seaberg and van 
der Kooy have failed to emerge. Much less controversial are 
findings reported by a number of groups that the neuronal 
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progeny of hippocarnpal progenitor cells are able to develop 
properties of mature, functional CNS neurons. Song, et al. 
2002 examined AHPCs and their progeny in vitro, observing that 
the new neurons showed electrical activity, morphology, and 
irnrnunochernical labeling consistent with forming functional 
synapses. Van Praag et al., 2002 conducted a similar study in 
vivo, using GFP and a retroviral vector to label HPCs and 
newly formed cells. The new neurons expressed neuronal 
markers TUJl and NeuN, exhibited appropriate synaptic 
morphology, and elicited action potentials. Mistry, et al. 
2002 examined E16 HPCs in vitro. After 21 days in 
differentiation conditions, the newly formed neurons expressed 
neurotransmitters, neurotransmitter receptors, and synaptic 
proteins. They formed elaborate networks with each other and 
spontaneously generated action potentials. 
A very recent study has examined the electrophysiological 
characteristics of AHPCs as they undergo the differentiation 
process. As the cells acquired a differentiated neuronal 
phenotype, they became excitable, and began expressing 
voltage-sensitive, tetrodotoxin-sensitive Na+ channels, low 
and high voltage-sensitive Ca++ channels, and delayed-
rectifier K+ channels. The authors maintain that the 
appearance of these several types of ion channels represents 
one of the most important steps in the stern cell to neuron 
transition (Hogg et al. 2004). 
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A fundamental question of relevance to stem cell 
transplantation is whether allogenic cells will be recognized 
as foreign by the host immune system. Klassen et al. 2003 
examined rat hippocampal progenitor cells in culture and found 
only minimal MHC Class I expression, and no detectable Class 
II expression. The rat HPCs did not elicit a response from 
human monocytes or spleen cells. Hori et al. 2003 
transplanted neural progenitor cells beneath the kidney 
capsule (an immunologically non-privileged site) of adult 
mice. The transplanted cells survived, did not sensitize the 
host, and failed to express either MHC Class I or Class II 
antigens. The brain is an immunologically privileged site, 
and transplants there also fail to elicit an immune response 
(Wenkel et al., 2000). 
A second question of relevance is whether the site into 
which stem cells are transplanted affects the types of stem 
cell progeny that can be generated. Neural stem and 
progenitor cells have been transplanted into several sites in 
adult animals, including spinal cord (Cao et al. 2001), 
striatum (Dziewczapolski et al. 2003), retina (Suzuki et al. 
2003), and hippocampal dentate gyrus (Shihabuddin et al. 
2000). A common finding is that neural stem cells 
transplanted to locations of adult neurogenesis display the 
ability to generate substantial numbers of both neurons and 
glia, whereas those transplanted to non-neurogenic regions 
typically form only glia, or mostly glia and only very few 
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neurons. Some studies have tried to prime stem cells with 
factors favoring neurogenesis, or utilize neuronal restricted 
progenitors, to allow neurons to be generated in non-
neurogenic regions; these approaches have been somewhat 
successful (Suzuki et al. 2003, Han et al. 2002). 
A third issue germane to transplantation is whether the 
newly generated cells can functionally integrate into the 
existing synaptic networks. Studies using hippocampal slice 
culture have suggested that embryonic stem cell-derived 
neurons (Benninger et al., 2003) and astrocytes (Scheffler et 
al., 2003) can functionally integrate into the surrounding 
tissue. Another study found functional integration of adult-
born neurons into the olfactory bulb (Carlen et al. 2002), 
lending further support to the idea that even in the adult 
brain, newly formed neurons are capable of inserting 
themselves properly into a pre-existing synaptic network. 
Despite the fact that neural stem cells have been 
transplanted into animal models of diseases such as 
Parkinson's Disease (Dziewczapolski et al. 2003) and ischemic 
stroke (Hoehn et al. 2002), transplantation studies using an 
APP-mutant mouse or other animal model of AD are lacking. 
Since the AD brain contains the neurotoxic compound AB, in 
vitro studies exposing NSCs to AB can therefore be useful in 
predicting what may happen to the cells in an in vivo AD 
model. 
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Prior studies examining the effects of arnyloid-beta on 
neural stern cells are limited to three published works. 
Haughey et al., 2002a show that A13 injected into the lateral 
ventricle of adult mice caused a decrease in migration, 
proliferation, and neurogenesis from neural stern cells of the 
subventricular zone. They also demonstrated a decrease in 
proliferation and differentiation, and an increase in 
apoptosis, when A13 was applied in vitro to cultured 
neurospheres from human embryonic cortex. Haughey et al., 
2002b showed similar decreases in neural stern cell 
proliferation and differentiation in the brains of mice 
expressing an APP mutation that increased brain A13 levels. 
Application of A13 to cultured mouse and human NSCs caused 
increased apoptotic cell death, and upregulation of caspases 
and calpains. Lopez-Toledano and Shelanski, 2004, exposed 
NSCs from rat striaturn and mouse hippocampus to A13 in vitro, 
noting that oligomeric A13 1-42 had a neurogenic effect - a 
directly contradictory conclusion to the work of Haughey et 
al., who maintain that A13 inhibits neurogenesis. 
Although these prior studies represent a starting point 
for further investigation, there are many issues that remain 
to be resolved. Further information on the effects of A13 on 
neural stem cells is needed before NSCs can be seriously 
considered for use in transplantation therapy for AD. 
Therefore, we have examined the effects of A13 on adult and 
embryonic neural stem cells from the same species (rat) and 
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same anatomical region (hippocampus). This permits a 
comparison between NSCs from two very different stages of 
development. We examined the effects of AJ3 on the viability, 
proliferation, and differentiation of the NSCs, since these 
are basic characteristics of the cells that may determine, in 
large part, the cells' suitability (or lack thereof) for 
transplantation into an AD brain environment. Our results are 
of interest both in terms of basic NSC biology, as well as 
when assessing the challenges that might be posed when 
introducing these cells into an in vivo environment containing 
substantial levels of AJ3. 
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CHAPTER 2: AMYLOID-BETA PEPTIDE AFFECTS VIABILITY 
AND DIFFERENTIATION OF EMBRYONIC AND ADULT 
RAT HIPPOCAMPAL PROGENITOR CELLS 
A paper to be submitted to Experimental Neurology 
Abstract 
James N. Eucher, Heather West Greenlee, 
Etsuro Uemura, and Donald S. Sakaguchi 
Neural stem cells (NSCs) have received recent attention 
due to their potential use in transplantation therapy for a 
number of neurological diseases. The Alzheimer's Disease (AD) 
brain is a uniquely challenging environment for transplanted 
cells due to the presence of amyloid-beta (AB) peptide, which 
is known to be toxic to neurons. The effects of AB on NSCs 
have just recently begun to be investigated. Here, we examine 
the effect of AB 25-35 on hippocampal progenitor cells (HPCs) 
from embryonic and adult rat. We also examine the effect of 
the tripeptide Gly-Pro-Arg (GPR) which has been reported to 
rescue primary culture neurons from AB-induced toxicity. HPCs 
exposed to AB in culture showed decreased viability as 
measured by MTT mitochondrial dehydrogenase assay; GPR was not 
protective against AB-induced viability loss. AB affected 
differentiation of adult, but not embryonic HPCs; adult HPCs 
exposed to AB expressed the neural stem cell marker Nestin at 
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higher levels than did controls. AB did not affect 
proliferation of embryonic HPCs, although GPR did suppress 
embryonic HPC proliferation. AB also did not show 
differential effects on proliferating neurons or glia, as 
determined by colabeling of BrdU and the neuronal marker MAP2 
or the astrocytic marker GFAP. Our findings suggest that AB 
decreases viability and affects differentiation of neural 
progenitor cells; however specific effects upon neurogenesis 
or NPC proliferation were not seen. 
Introduction 
The neurological deficits that are characteristic of 
Alzheimer's Disease (AD) are ultimately a result of neuronal 
loss in distinct anatomical regions of the brain. For this 
reason, neural stem cell (NSC) transplantation therapy has 
been proposed as a possible therapeutic approach (for review, 
see Suguya, 2003). The AD brain represents a particularly 
inhospitable environment for transplanted cells, as it 
contains beta-amyloid (AB), a small protein of 39-43 amino 
acids in length (Yankner, 1996). The toxic effects of AB on 
neurons have been demonstrated in vitro as well as in vivo, on 
several cell types of the brain including neurons (Pike, 1995; 
Walsh, 2002), astrocytes (Abramov, 2003; Nagele, 2003), and 
oligodendrocytes (Xu, 2001). Data concerning the effects of 
AB on NSCs, however, is still sparse. A study that examined 
cultured human and mouse NSCs (Haughey, 2002) suggested that 
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AJ3 disrupted neurogenesis and impaired NSC proliferation. A 
different study using cultured rat and mouse NSCs reached the 
opposite conclusion, suggesting that Afl's effects on NSCs were 
neurogenic, and did not impair proliferation (Lopez-Toledano, 
2004). Comparisons between these earlier studies are 
complicated by the use of NSCs from three different species, 
obtained at a number of different developmental stages, and 
taken from several different anatomical regions within the 
brain. To further clarify how AJ3 may affect NSCs, we have 
examined its effects on NSCs isolated from one species (rat), 
from the same location (hippocampus), at two different time 
points (embryonic day 17 and adulthood). We also examined the 
effect of the tripeptide Gly-Pro-Arg (GPR) on NSCs; GPR has 
recently been reported to rescue cultured hippocampal neurons 
from AB-induced toxicity (Ioudina and Uemura, 2003). Our data 
suggest that AJ3 affects viability and differentiation of NSCs 
from rat hippocampus, and that these effects differ based on 
the developmental stage from which the NSCs are obtained. 
However, our data does not indicate any particular effect of 
AJ3 upon neurogenesis, nor does AJ3 appear to affect NSC 
proliferation. GPR does not appear to rescue NSCs from 
viability loss due to Afl; in addition, GPR may have a moderate 
degree of effects on NSC differentiation. 
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Materials and Methods 
Hippocampal progenitor cell isolation and culture 
Adult HPCs (AHPCs; Palmer et al., 1997) were a gift from 
Dr. Fred Gage, The Salk Institute, and were typically obtained 
at approximately seven passages. Embryonic HPCs (EHPCs) were 
isolated at Iowa State University. 17-day timed-pregnant HSD 
rats were anesthetized with halothane and the uteri were 
removed. Fetuses were removed and their hippocampi were 
dissected out. Tissues were digested in 0.25% trypsin for 15 
min at room temperature, followed by 5 minutes in 2 mg/ml 
trypsin inhibitor. Neurobasal/B27 media was added and tissues 
were dispersed by trituration with a fire-polished glass 
pipette. EHPCs were then placed in tissue culture flasks. 
Each flask was filled with 15 ml of EHPCs suspended in culture 
media. 
Both cell types were maintained in growth media 
consisting of Dulbecco's Modified Eagle Medium/Ham's F12 
(DMEM/F12, Invitrogen) supplemented with EGF (Invitrogen) at 
40 ng/ml and bFGF (Promega) at 20 ng/ml. Every two days, 
fresh media was added to the flasks. Cells were passaged 
weekly and were typically used for experiments between P8-P12 
(AHPCs) or P3-P7 (EHPCs). 
For experiments, cells were plated onto coverslips (for 
ICC) or directly into 24-well plates (for MTT) coated with 
polyethyleneimine (PEI, Sigma). Differentiation media used 
consisted of Neurobasal media with B27 supplement 
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(Invitrogen), and contained bFGF at 5 ng/ml. Cells were 
allowed 24 hours after plating to adhere to the PEI substrate 
before any treatments were added. Cells were allowed to 
differentiate for 3 or 7 days before processing. In the case 
of 7-day groups, 1/2 of the media in each well was replaced, 
and cells were re-treated, three days after the first 
treatment. 
Cell treatments 
Cells listed as receiving amyloid were treated with 1 or 
10 µM A13 25-35 (Bachem), which had been allowed to pre-
aggregate at 37 °C for a minimum of one week (Pike et al., 
1995). Cells listed as receiving GPR were treated with 
synthetically produced Gly-Pro-Arg tripeptide (Bachem) at a 
concentration of 50 µM. Cells labeled with Bromodeoxyuridine 
(BrdU) were treated with BrdU at a concentration of 10 µM. 
MTT Viability Assay 
After 3 or 7 days, cells were processed for the MTT 
mitochondrial reduction assay. This assay is based on the 
ability of active mitochondrial dehydrogenases to convert the 
yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) to water-insoluble purple 
formazan crystals. The degree of conversion of yellow MTT to 
purple product is indicative of a cell's mitochondrial 
activity, and provides an estimate of the cell's overall 
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viability (Abe, 1999). Cells were incubated with MTT (Sigma) 
for 4 hours at 37°C. The crystals were then dissolved in 
isopropanol; the solution was aspirated and transferred to a 
96-well plate, and absorbance was measured on a Molecular 
Devices SpectraMax 190 spectrophotometer, at a wavelength of 
570 nm, with background subtracted at 630 nm. 
Single-label immunocytochemistry 
All staining procedures were performed at room 
temperature. For single-label ICC, cells were fixed with 4% 
paraformaldehyde for 20 min and then rinsed 3 times (10 min 
each) in 50 mM KPBS (Potassium Phosphate Buffered Saline; per 
1 L double-distilled water, contains NaCl 9.00 g/L, K2HPO 4 5.85 
g/L, KH 2PO4 2.25 g/L). Cells were incubated in blocking 
solution (consisting of KPBS as solvent; per 1 L KPBS, 
contains normal donkey serum (NDS, Jackson) at 0.9 g/L, bovine 
serum albumin at 10.0 g/L, Triton-X 100 at 4.28 g/L) for 2 
hrs. Primary antibodies were then added (Mouse anti-Nestin, 
MAP2, GFAP, RIP) and cells were incubated for 20 hrs. The 
following day cells were rinsed 3 times (10 min each) in 50 mM 
KPBS containing Triton-X 100 at .214 g/L (KPBS-TrX). 
Secondary antibody was then added (Biotinylated Donkey anti-
Mouse, 1:600, Jackson) and cells incubated for 2 hrs. Cells 
were rinsed 3 times (10 min each) in KPBS-TrX, and then 
incubated in KPBS-TrX containing Cy3-Avidin (Jackson) at 
1:5000 concentration for 30 min. Cells were washed 3 times in 
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KPBS (each 10 min), then once (for 5 min) in KPBS containing 
4' ,6-diamidino-2-phenylindole (DAPI, Molecular Probes) at 
1:333 concentration to label cell nuclei. After three more 
washes in KPBS (5 min each) coverslips were mounted to glass 
slides using VectaShield mounting media (Vector Laboratories). 
Primary antibody concentrations were as follows (all are mouse 
monoclonals): a-Nestin clone 401, 1:10 (Developmental Studies 
Hybridoma Bank, University of Iowa); a-MAP2ab, 1:750 (Sigma); 
a-GFAP, 1:2400 (Sigma); a-RIP, 1:125 (Developmental Studies 
Hybridoma Bank, University of Iowa). 
Double-Label BrdU Immunocytochemistry 
All staining procedures were performed at room 
temperature. For double-label ICC, cells were fixed with 70% 
ethanol for 30 min, and then rinsed twice (5 min each) in 50 
mM KPBS. Cells were incubated in 2.0 N HCl for 15 min, and 
then in 0.1 M sodium borate for 5 minutes. Cells were rinsed 
twice (5 min each) in KPBS and incubated in blocking solution 
containing normal goat serum (NGS, Jackson) for 2 hrs. 
Primary antibody was then added (rat anti-BrdU) and cells were 
incubated for 20 hrs. The following day cells were rinsed 3 
times (10 min each) in KPBS-TrX. Secondary antibody 
(Biotinylated Goat anti-Rat, 1:200, Jackson) was applied and 
cells incubated for 2 hrs. Cells were rinsed 3 times (10 min 
each) in KPBS-TrX, and then incubated in KPBS-TrX containing 
Cy2-Avidin (Jackson) at 1:750 concentration for 30 min. Cells 
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were rinsed 3 times (10 min each) in KPBS, and then incubated 
in a blocking solution containing normal donkey serum (NDS) 
for 2 hrs. Primary antibody was then added (Mouse anti-
Nestin, MAP2, GFAP) and cells were incubated for 20 hrs. The 
third day, cells were rinsed 3 times (10 min each) in KPBS-
TrX. Secondary antibody (Cy3-conjugated Donkey anti-Mouse, 
1:250, Jackson) was applied and cells incubated for 2 hrs. 
Cells were washed 3 times in KPBS-TrX (each 10 min), then once 
(for 5 min) in KPBS containing 4' ,6-diamidino-2-phenylindole 
(DAPI) at 1:333 concentration to label cell nuclei. After 
three more washes in KPBS (5 min each) coverslips were mounted 
to glass slides using VectaShield mounting media. Primary 
antibody concentrations were as follows: Polyclonal rat a-
BrdU, 1:200 (Accurate Chemical and Scientific Co.); monoclonal 
mouse a-Nestin clone 401, 1:10 (Developmental Studies 
Hybridoma Bank, University of Iowa); monoclonal mouse a-
MAP2ab, 1:75 (Sigma); monoclonal mouse a-GFAP, 1:240 (Sigma). 
Fluorescent Imaging/ Cell Quantification 
Cells were visualized using a Nikon Eclipse E800 
fluorescent microscope. For each coverslip, cells in 16 
random fields under 40x oil-immersion objective were counted. 
Data collected for each coverslip included total number of 
cells (based on DAPI staining), number of cells immunopositive 
for each marker, _and percentage of cells immunopositive for 
each marker. Images were obtained using a Q-Imaging Retiga 
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1300 digital camera, and processed on a Macintosh G4 computer 
using OpenLab 3.1.3 (Improvision), Photoshop 8.0 (Adobe), and 
Freehand MX 11.0 (Macromedia). 
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RESULTS 
Amyloid-beta 25-35 causes decreased viability in HPCs. 
We tested the effect of treatment with A.13 25-35, as well 
as treatment with the GPR peptide, on HPC viability, as 
measured by the MTT mitochondrial dehydrogenase assay. This 
assay allows assessment of mitochondrial dehydrogenase 
activity; a decrease in activity suggests a loss of cellular 
viability (Abe, 1999). Cultured AHPCs or EHPCs were treated 
with 1 or 10 µM A.13, with or without 50 µM GPR peptide. 
Viability was assayed via the MTT assay at either 3 or 7 days 
after the first treatment. EHPCs showed significantly 
decreased viability relative to controls at 3d when treated 
with 10 µM A.13 (P<.0034), 1 µM A.13 + 50 µM GPR (P<.016), or 10 
µM A.13 + 50 µM GPR (P<.002) (Fig. lA). At 7d, EHPC viability 
in the same treatment groups was also significantly decreased 
(P values respectively are P<.0034, P<.0194, P<.002) relative 
to controls (Fig. lB). AHPCs showed significantly decreased 
viability relative to controls at 3d when treated with 10 µM 
A.13 + 50 µM GPR (P<.0205) (Fig. lC). At 7d, AHPC viability was 
decreased relative to controls when treated with 1 µM A.13 
(P<.0039), 10 µM A.13 (P<.002), or 10 µM A.13 + 50 µM GPR 
(P<.0111) (Fig. 1D). For all MTT experiments, MTT values for 
untreated controls were set at 100%. Also, in all experiments 
an additional control, consisting of treatment with 50 µM GPR, 
but no A.13, was included. In no case was viability 
significantly decreased by 50 µM GPR alone. These data 
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Figure 1: MTT viability data for 3d and 7d EHPCs (A, C), and 
3d and 7d AHPCs (B, D). Results are expressed at percentage 
of control value, which is set at 100%. EHPCs show 
significantly decreased viability after treatment with 10 µM 
AJ3, 1 µM AJ3 + 50 µM GPR, or 10 µM AJ3 + 50 µM GPR, and this 
effect is similar at both 3d and 7d time points. AHPCs show 
significantly decreased viability at 3d after treatment with 
10 µM AJ3 + 50 µM GPR; at 7d, significant effects are also seen 
in 1 µM AJ3 and 10 µM AJ3 groups. Treatment means (n=3) are 
compared to control means; * = P<.05. 
57 
A B 
3d EHPCs 3dAHPCs 
140 140 
~ 120 ~ 120 
-a -,-~ 100 :> 100 
E 80 i 80 8 u u 60 
'8 60 
'8 
" 41 J 1· 40 40 
I 20 I 20 
0 0 
I - ,:, ~ ~ ~ I - ,:, ~ ~ ~ ~ - ~ -~ ~ + + + + u l""I ,:, u l""I ,:, ~ • ~ • ~ ~ 
Treatment Treatment 
C 7d EHPCs D 7dAHPCs 
140 140 
~ 120 ~ 120 T 
-a 
-a ::> 100 :> 100 i 80 I 80 ~ 60 u 60 
'a 41 
" I 40 I 40 20 20 
0 0 
I - ,:, ~ ~ ~ I - ,:, ~ ~ ~ ~ - ~ -~ ~ + + + + u l""I ,:, u l""I ,:, 
~ • ~ • ~ ~ 
Treatment Tl'eatment 
58 
suggest that AB significantly decreases EHPC viability by 3d, 
and that the GPR peptide is not protective against this 
effect, and may partially contribute to it when combined with 
A.13 (A.13 1 µMalone did not lead to significantly decreased 
viability, but AB 1 µM + 50 µM GPR did). These effects 
persist when EHPC viability is assayed at 7d. The data 
suggest that AB may take longer to affect AHPC viability - at 
3d, only AB 1 µM + 50 µM GPR led to significantly decreased 
viability relative to controls. At 7d, AHPCs treated with 1 
µM A.13, 10 µMAB, or 10 µMAB+ 50 µM GPR showed significantly 
decreased viability relative to controls. The effect of the 
GPR peptide, in combination with A.13, on AHPC viability is less 
clear. At 3d, AHPCs receiving 10 µMAB+ 50 µM GPR had 
significantly decreased viability, while those receiving 10 µM 
A.13 alone did not. However at 7d, AHPCs receiving 1 µM A.13 
alone had significantly decreased viability, while those 
receiving 1 µMAB+ 50 µM GPR did not. Thus, for both cell 
types, A.13 most commonly decreases viability, while the GPR 
peptide has no effect alone, but may contribute to decreased 
viability in combination with AB. 
Amyloid-beta 25-35 affects differentiation of adult, but not 
embryonic, HPCs. 
To determine whether differentiation profiles of HPCs are 
affected by A.13 25-35 or GPR peptide, single-label 
immunocytochemistry was performed either 3d or 7d after 
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Figure 2: Representative single-label ICC images for EHPCs at 
7 days in differentiation conditions. Bar= 20 µmin each 
image. Columns show treatment applied (control, 10 µMAB 
alone, both 10 µMAB and 50 µM GPR, 50 µM GPR alone. Rows 
show antibody labeling for Nestin (neural stem cells), MAP2 
(neurons), GFAP (astrocytes), and RIP (oligodendrocytes). 
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Fig. 2, continued: Representative single-label ICC images for 
AHPCs at 7 days in differentiation conditions. Bar= 20 µmin 
each image. Columns show treatment applied (control, 10 µM A.13 
alone, both 10 µM A.13 and 50 µM GPR, 50 µM GPR alone. Rows 
show antibody labeling for Nestin (neural stem cells), MAP2 
(neurons), GFAP (astrocytes), and RIP (oligodendrocytes). 
62 
Control Amyloid Both GPR 
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initial treatment with 10 µM AJ3, 50 µM GPR, or 10 µM AJ3 + 50 
µM GPR. Representative ICC images are shown in Fig. 2A for 
EHPCs; in Fig. 2B for AHPCs. Cells were stained with cell-
type specific antibodies against Nestin (neural stem cells), 
MAP2 (neurons), GFAP (astrocytes), and RIP (oligodendrocytes) 
(Fig. 2A, EHPCs; Fig. 2B, AHPCs). 
Control percentages for 3d EHPCs were Nestin 49.28 +/-
4.57%; MAP2 22.85 +/- 8.65%; GFAP 16.63 +/- 2.94%; RIP 8.89 
+/- 1.45%. Control percentages for 3d AHPCs were Nestin 72.40 
+/- 7.68%; MAP2 6.88 +/- 2.87%; GFAP 0.22 +/- 0.22%; RIP 19.50 
+/- 7.90%. At 3d, no effect was observed in either cell type, 
for any antibody, among all treatment groups. 
Control percentages for 7d EHPCs were Nestin 58.48 +/-
4.35%; MAP2 32.54 +/- 7.70%; GFAP 21.33 +/- 2.19%; RIP 4.93 
+/- 1.84%. Control percentages for 7d AHPCs were Nestin 48.17 
+/- 3.50%; MAP2 0.71 +/- 0.28%; GFAP 4.07 +/- 3.77%; RIP 51.72 
+/- 6.87%. At 7d, EHPCs treated with 50 µM GPR showed 
significantly fewer MAP2-positive cells (11.38 +/- 3.06%; 
P<.0085) relative to controls. None of the EHPCs receiving 
treatment with 10 µM AJ3 or 10 µM AJ3 + 50 µM GPR showed 
significant differences relative to controls (Fig. 3B). At 
7d, AHPCs treated with 10 µM AJ3 or 10 µM AJ3 + 50 µM GPR showed 
significantly more Nestin-positive cells (respectively, 69.05 
+/- 2.52%, P<.0138; 66.46 +/- 9.10%, P<.0269) than did 
controls. AHPCs treated with 10 µM AJ3 + 50 µM GPR also showed 
significantly more MAP2-positive cells (15.22 +/- 6.02%, 
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Figure 3: Single-label immunocytochemistry data for 3d and 7d 
EHPCs (A, B). Comparisons were made between treatment means 
and control mean (n=4 or n=S) within each antibody. For 3d 
EHPCs, treatment means were not significantly different from 
control means for any antibody. For 7d EHPCs, cells treated 
with 50 µM GPR showed significant less MAP2 expression than 
did controls; * = P<.05. Treatment means were not 
significantly different from control means for other 
antibodies at 7d. 
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Figure 3, continued: Single-label immunocytochemistry data for 
3d and 7d AHPCs (C, D). Comparisons were made between 
treatment means and control mean (n=4 or n=5) within each 
antibody. At 3d, treatment means were not significantly 
different from control means for any antibody. At 7d, cells 
treated with 10 µMAB or 10 µMAB+ 50 µM GPR showed 
significantly more Nestin expression than controls. Cells 
treated with 10 µMAB+ 50 µM GPR showed significantly more 
MAP2 expression than controls. * = P<.05. 
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P<.0254) than did controls. None of the AHPCs receiving 
treatment with 50 µM GPR alone showed significant differences 
relative to controls (Fig. 3D). Taken together, our results 
indicate that A13 does not affect EHPC or AHPC differentiation 
when assayed 3d after treatment. At 7d after treatment, EHPC 
differentiation is not affected by AB, while AHPC 
differentiation is affected by AB, and the effect is not 
rescued by GPR. 
Amyloid 25-35 does not affect EHPC proliferation, while GPR 
decreases EHPC proliferation. 
To ascertain whether AB or GPR affects cell 
proliferation, BrdU labeling of cell proliferation ICC was 
performed on EHPCs 7d after initial treatment with 10 µM A13, 
10 µMAB+ 50 µM GPR, or 50 µM GPR. BrdU was added with 
either the first treatment, at Day 0, or the re-treatment, at 
Day 3. ICC with an antibody directed against BrdU was done 
after culture termination on day 7. ICC on EHPCs which 
received BrdU at Day 0 (Fig. 4A) revealed a significant 
decrease in cell proliferation (as measured by percentage of 
total cells positive for BrdU) in groups treated with 10 µM A.13 
+ 50 µM GPR (P<.0001), or 50 µM GPR alone (P<.0011), relative 
to controls. ICC on EHPCs which received BrdU at Day 3 (Fig. 
4B) revealed a significant decrease in cell proliferation only 
in the group treated with 50 µM GPR (P<.0018). The group 
treated with 10 µM A13 + 50 µM GPR showed a mean percentage 
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Figure 4: BrdU incorporation data for EHPCs; BrdU ICC was 
performed 7d after initial treatment with AJ3 and/or GPR; cells 
were labeled with BrdU at Day 0 (A) or Day 3 (B). For each 
set of experiments, treatment means (n=4 or n=5) are compared 
to control means. For cells receiving BrdU at Day 0, 
treatment groups receiving 10 µM AJ3 + 50 µM GPR, or 50µM GPR 
alone, showed significantly lower percentage of cells 
immunoreactive for BrdU than did controls. For cells 
receiving BrdU at Day 3, the treatment group receiving 50 µM 
GPR showed significantly lower percentage of cells 
immunoreactive for BrdU than did controls. * = p<.05. 
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BrdU-positive cells that was intermediate between values 
observed for control and 50 µM GPR groups, but this value was 
not significantly decreased relative to the control group. 
These data suggest that when EHPC proliferation is measured 
during the timeframe immediately following initial treatment, 
cells receiving both A13 10 µM + 50 µM GPR, as well as 50 µM 
GPR alone, show significantly less proliferation as measured 
by BrdU incorporation. When EHPC proliferation is measured 
during the timeframe immediately following the 3d re-
treatment, cells treated with 50 µM GPR alone show 
significantly less proliferation relative to controls. These 
results indicate that A13 does not effect EHPC proliferation in 
differentiation conditions. 
Amyloid 25-35 does not affect proportion of proliferating 
cells that colabel with neuronal or astroglial markers 
To determine what cell phenotypes constituted the cells 
that took up BrdU in culture, double-label immunocytochemistry 
was performed on 7d EHPCs. BrdU was applied at either Day 0 
or Day 3; at Day 7 cells were double-stained with antibodies 
to BrdU and one of the following: Nestin, MAP2, or GFAP (Fig. 
5). Comparisons were made between time points and treatments 
for each of the three antibodies. Values are expressed as the 
percentage of BrdU-positive cells also positive for Nestin, 
MAP2, or GFAP. 
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Figure 5: Representative double-label ICC images for EHPCs at 
7d. Images are from control cells with BrdU added at Day 0. 
Columns show cells labeled with first antibody (red), BrdU 
(green), DAPI (blue), and all three (merged images). Rows 
show cells irnrnunoreactive for the following three first 
antibodies: Nestin (neural stern cells), MAP2 (neurons), GFAP 
(astrocytes). 
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Comparison data for Nestin is shown in Fig. 6A. For the 
group given BrdU at Day 0, cells treated with 10 µMAB+ 50 µM 
GPR showed significantly increased Nestin/BrdU colabeling 
(P<.0262) relative to controls. For the group given BrdU at 
Day 3, none of the treated groups shows significantly 
different Nestin/BrdU colabeling relative to controls, 
suggesting that by 3 days after the initial treatment, Nestin-
positive cells represent a similar portion of BrdU-positive 
cells for all treatment groups. 
Comparison data for MAP2 is shown in Fig. 6B. For the 
group given BrdU at Day 0, none of the treated groups shows 
significantly different MAP2/BrdU colabeling relative to 
controls. For the group given BrdU at Day 3, the cells 
treated with 50 µM GPR alone show significantly decreased 
MAP2/BrdU colabeling (P<.0304) relative to controls. This 
suggests that by 3 days after initial treatment, GPR-treated 
cells have a smaller proportion of BrdU-positive cells that 
colabel with MAP2, relative to all other treatment groups. 
Comparison data for GFAP is shown in Fig. 6C. At both 
BrdU timepoints, none of the various treatments induces 
significantly different amount of GFAP/BrdU colabeling 
relative to controls. 
As a group, these experiments demonstrate that AB does 
not effect the percentage of BrdU-positive, proliferative 
cells that also express either the neuronal marker MAP2 or the 
astroglial marker GFAP. GPR affected only division of cells 
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Figure 6: Double-label imrnunocytochemistry data for 
Nestin/BrdU (A), MAP2/BrdU (B), and GFAP/BrdU (C). Data are 
expressed as percent of BrdU+ cells also Nestin+, MAP2+, or 
GFAP+. Data from groups given BrdU at Day 0 and Day 3 are 
presented side-by-side to allow for visual comparison. Cells 
treated with 10 µM AJ3 + 50 µM GPR showed significantly more 
Nestin/BrdU colabeling relative to control cells, among Day 0 
BrdU group (Fig 6A). Cells treated with 50 µM GPR showed 
significantly less MAP2/BrdU colabeling relative to control 
cells, among Day 3 BrdU group (Fig 6B). All significance 
calculations are made within Day 0 or Day 3 groups; amyloid, 
amyloid + GPR, and GPR treatments are compared against 
untreated controls (n=4 or n=5). * = P<.05. 
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expressing one marker (MAP2) at one BrdU time point (Day 3), 
and only when applied alone, but not when applied with Afl. 
The combination of Afl + GPR affects Nestin/BrdU colabeling, 
but only at the earlier BrdU time point (Day O); this effect 
seems not to be present at the later time point (Day 3). 
In summary, Afl does not affect the proportion of 
proliferating cells (as measured by BrdU incorporation) that 
colabel with the neuronal marker MAP2 or the astroglial marker 
GFAP. 
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Discussion 
The two prior studies examining arnyloid effect on neural 
stern cells have reached essentially opposite conclusions. 
Haughey et al., 2002a,b (considered together as one connected 
study) report that arnyloid impairs NSC neurogenesis and 
proliferation. Conversely, Lopez-Toledano and Shelanski, 2004 
report that arnyloid has the opposite effects. Our results 
largely fall in between these extremes. It is important to 
note that of the three groups that have investigated this 
topic, each has utilized different cell populations, isolated 
from different species, anatomical regions, and developmental 
stages. 
Our data from the MTT viability assay suggests that A.13 
causes some loss of viability in NSCs, but is not fatal to 
them - the MTT value for dead cells is zero. With both EHPCs 
and AHPCs, a consistent finding was that exposure to A.13 caused 
MTT levels to drop significantly; however, very rarely did 
they go below 60% of control values within the timeframe of 
the longest experiments (7d exposure to A.13). Haughey et al., 
2002b shows a threefold increase in apoptosis in NSCs exposed 
to A.13 relative to controls. Lopez-Toledano and Shelanski, 
2004, report no significant increase in apoptosis after A.13 
treatment. Although our experiments did not include direct 
measurements of cell death, prior studies have been done in 
our lab using the lactate dehydrogenase (LDH) cell death assay 
to examine neonatal murine brain progenitor cells. This 
79 
murine NPC line shows no increase in LDH levels when treated 
with AB (Uemura et al., unpublished observation). Conversely, 
treatment of primary culture neurons with AB is characterized 
by rapid and substantial increase in LDH levels due to loss of 
membrane integrity and death (Ioudina and Uemura, 2003). 
These observations suggest a physiological difference exists 
between NSCs and mature neurons, such that NSCs are not fully 
susceptible to the effects of AB that are so deleterious to 
neurons. 
AB's influence on NSC differentiation was dissimilar 
between the two cell populations. Differentiation of EHPCs 
was not affected by AJ3 at any point studied. Conversely, AHPC 
differentiation was unaffected at 3d, but by 7d cells treated 
with AB showed increased Nestin expression relative to 
controls, while cells treated with AB and GPR in combination 
showed increased Nestin expression and increased MAP2 
expression. One possible explanation for these results is 
that AHPCs exposed to AB compensate by retaining Nestin 
expression for a longer time. Nestin is typically used as a 
marker for undifferentiated neural stem cells (Duittoz, 2001), 
although several authors have recently suggested that Nestin 
expression may continue even after a cell begins to express 
proteins such as GFAP that are thought of as markers of more 
differentiated cells (Seri et al., 2001; Fillippov et al., 
2003; Steiner et al., 2004). It is possible that retention of 
Nestin is associated with retention of other undifferentiated 
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characteristics, some of which may reduce a cell's 
vulnerability to A13-induced toxicity. If so, it might suggest 
the existence of a usurvival mode" for stem cells exposed to a 
difficult environment such as one with high levels of AB. 
Because A13 did not affect EHPC differentiation at all, it is 
possible that these cells have not yet developed the cellular 
machinery through which A13 acts to affect differentiation, 
while the same machinery may be present, at least to some 
extent, in AHPCs. 
Our experiments with EHPCs suggest that A13 does not 
affect NPC proliferation, which is consistent with the 
observations of Lopez-Toledano and Shelanski, 2004. Exposure 
to GPR alone, however, did cause a significant decrease in 
proliferation when BrdU was present in the media at Day O or 
Day 3. The combination of A13 + GPR also caused significant 
decrease in proliferation at Day O, but this effect was no 
longer present at Day 3. This is a somewhat unexpected 
observation in light of the fact that the GPR tripeptide is 
biochemically very similar to another tripeptide, GPE, that is 
a product of IGF-1 (Ioudina and Uemura, 2003). IGF-1, in 
turn, has shown to be necessary for the proliferation of 
neural stem cells (Arsenijivic et al., 2001). Further studies 
might elucidate the mechanism through which GPR appears to 
inhibit proliferation of NSCs. 
Double-label immunocytochemistry was performed to examine 
the possibility that A13 and/or GPR might selectively affect 
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the proliferation of either neurons or glial cells. Cells 
were labeled with BrdU and either Nestin, MAP2, or GFAP. AB 
failed to affect the percentage of cells co-expressing either 
BrdU and MAP2 or BrdU and GFAP. GPR alone caused a 
significant decrease in coexpression of MAP2 and BrdU, but 
only at the Day 3 BrdU time point. In total, the effects of 
AB or GPR on the coexpression of MAP2 or GFAP with BrdU were 
very minimal, suggesting that there is not a differential 
effect on the proliferation of either neuronal or glial cells. 
This is in contrast to the findings of Haughey et al., 2002b, 
who reported that exposure to AB selectively decreases the 
population of NSCs that colabel with Brdu and E-NCAM, another 
neuronal marker. 
In summary, the results of our study are very distinct 
from those reported previously by Haughey et al., 2002a,b as 
well as Lopez-Toledano and Shelanski, 2004. Our results 
highlight the differences that exist between neural stem cells 
isolated from dissimilar stages of development, even if taken 
from the same species and anatomical region. These results 
also underscore the heterogeneity of the large number of cell 
types collectively conceptualized as "neural stem cells". It 
is likely that each distinct NSC line/population may have a 
unique degree of tolerance for AB. This would argue for the 
necessity of in vitro characterization studies, in the 
presence of AB, for any neural stem cell line under 
investigation as a candidate for AD transplantation therapy. 
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CHAPTER 3: GENERAL CONCLUSIONS 
General Discussion 
We are one of the first three groups to examine the 
effects of AB on neural stem cells in vitro. A group from 
Johns Hopkins University conducted the first experiments in 
2002, producing two closely related publications (Haughey et 
al., 2002a; Haughey et al., 2002b). This group examined 
cultured progenitor cells from human fetal cortex, mouse 
embryonic brain, and mouse cerebellum. In summary, they 
concluded that AB decreased neurogenesis and inhibited 
proliferation. A group from Columbia University published 
their findings earlier this year (Lopez-Toledano and 
Shelanski, 2004). They examined cultured progenitor cells 
from embryonic rat striatum and neonatal mouse hippocampus. 
This group reported a neurogenic effect of AB on their NPCs, 
with no effect on proliferation. Our results represent a 
third set of conclusions. Examining hippocampal progenitor 
cells, from embryonic and adult rat, we found that although AB 
did affect viability and differentiation, it did not 
specifically affect neurogenesis, nor did it affect NPC 
proliferation. 
The data collected from our study, considered in 
conjunction with the two prior works, permits some general 
overarching conclusions to be drawn. The first is that NPCs 
in culture appear able to tolerate AB in their environment. 
This stands in sharp contrast to prior studies examining the 
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effect of AJ3 on cultured neurons, which uniformly demonstrate 
that neurons find AJ3 very toxic and are killed by AJ3 at high 
nanomolar to moderate micromolar concentrations (Yankner et 
al., 1989; Loo et al., 1993; Ueda et al., 1994; Ioudina and 
Uemura, 2003). Our data suggests that although exposure to AJ3 
causes decreased HPC viability, as measured by MTT reduction, 
the viability rarely drops below 60% of controls after one 
week of AJ3 exposure; conversely, cultured neurons undergo 
substantial degeneration and death after only 24 hours 
exposure to AJ3 (Loo et al., 1993). Although Haughey et al., 
2002a and 2002b report an increase in apoptosis among NPCs 
exposed to AJ3 in culture, the cells that express markers of 
apoptosis still represent only a fraction of their total 
cells. Our group has exposed murine NPCs to AJ3 for up to one 
week; this exposure causes no increase in cell death as 
measured by lactate dehydrogenase (LDH) assay (Uemura et al., 
unpublished observation). In a general sense, then, although 
NPCs tend to show some indicators of physiological stress when 
exposed to AJ3, they survive in its presence at concentrations 
which are lethal to neurons. 
A second general conclusion is that NPCs will generally 
yield at least some neurons when differentiated in an 
environment containing AJ3. All three groups which have 
conducted experiments of this type thus far have obtained 
differentiated cells which have gross morphological features 
consistent with neurons and that express neuronal marker 
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antigens such as TUJl, MAP2, and NeuN. This is of obvious 
importance in terms of the feasibility of NSC transplants for 
Alzheimer's Disease, since the primary goal of this approach 
is to induce the transplanted NSCs to produce new neurons to 
replace endogenous neurons that are lost to the disease 
(Suguya, 2003; Rice et al., 2003; Limke and Rao, 2003). Had 
these early studies instead suggested that NSCs are incapable 
of generating new neurons in an environment containing Afl, it 
would have represented a substantial roadblock to the idea of 
transplantation therapy for AD. However, further studies need 
to be made to ascertain that these putative neurons possess 
the proper physiological characteristics, such as ability to 
generate action potentials. Obviously, cells that have 
neuron-like morphology but cannot produce action potentials 
will not be of therapeutic benefit. 
A third general conclusion that can be made is that 
different lines of stern cells respond to AJ3 in different ways 
- that is, that the effect of AJ3 is far from uniform on all 
neural stern cells. This is not altogether surprising, given 
that the three studies have utilized neural stern/progenitor 
cells from different species, developmental stages, and 
anatomical regions. Prior experiments have shown that the 
differentiation patterns of progenitor cells from the same 
species, developmental stage, and anatomical region (rat 
embryonic hippocarnpus) can be drastically altered by changing 
the differentiation media utilized (Eucher et al., unpublished 
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data; see Appendix). One consistent theme that has emerged 
from the literature over the past several years is that what 
are broadly categorized as uneural stern cellsu represent an 
incredibly heterogeneous group of cells, with behavior that 
can vary widely based on the innate biology of each cell line, 
as well as influences such as culture media, presence of 
growth factors, cell density, growth substrate, etc. 
Owing to the substantial diversity of neural stern cells, 
it is desirable that any candidate line for transplantation 
therapy should first be examined in an in vitro system to 
assess its response to AB. Further studies of NSCs 
transplanted into in vivo AD model systems then represent the 
next logical step. Much work remains to be done before 
transplantation of NSCs into an actual AD patient can be 
attempted. Our study, as well as the aforementioned other 
early studies, represents a first step in the direction of 
this ultimate goal. The ability of neural stern cells to 
survive and differentiate in vitro, despite the presence of AJ3 
in their environment, confirms their therapeutic potential for 
the treatment of Alzheimer's Disease. 
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Recommendations for Future Research 
A number of further experiments can be suggested based 
upon questions raised by our results. Because "neural stem 
cells" are a very heterogeneous group, with wide differences 
between cell lines, any NSC line under study as a candidate 
for transplantation therapy should first be thoroughly 
characterized in vitro, both in the absence and presence of 
A£, preferably at a range of AJ3 concentrations since the exact 
physiological concentration of amyloid is not known and is 
likely to be widely variable. 
NSCs such as our EHPCs and AHPCs that have been 
characterized in vitro should be transplanted into an 
established in vivo AD model organism such as APP-
overexpressing mouse. Survival, differentiation, integration, 
and physiological function of the transplanted NSCs and their 
progeny should be assessed. Threats to the safety of the 
transplant recipient, such as tumor formation, should be 
searched for carefully. 
NSCs that show promise in an in vivo AD model system 
should be transplanted into more complex species such as the 
geriatric cat or monkey. Continued success and safety in 
these systems would eventually suggest that transplantation to 
the human AD brain should be attempted. A quality-of-life 
improvement in an AD patient receiving transplanted neural 
stem cells represents the ultimate realization of their 
therapeutic potential. 
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APPENDIX 
Media Comparison 
As a first step in our experiments, it was necessary to 
decide on a particular formulation for the media used to 
differentiate the HPCs. Two different formulas had been in 
general use in our lab prior to the beginning of the 
experiments described in Chapter 2. 
The first formula utilized Gibco Dulbecco's Modified 
Eagle Medium with F12 Supplement (DMEM/Fl2). Also present in 
this media was glucose, fetal bovine serum, nystatin, N2 
supplement, L-glutamine, penicillin, and streptomycin. 
The second formula utilized Gibco Neurobasal media. Also 
present in this media was B27 supplement, L-glutamine, L-
glutamate, and a small concentration of basic fibroblast 
growth factor (bFGF). 
In order to make a meaningful comparison between the two 
media formulas, a single HPC type was used. E17 hippocampal 
progenitors (EHPCs) were utilized because they were plentiful 
in the culture laboratory at the time of these experiments. 
EHPCs were isolated and kept in growth media for several 
passages (typically between 3 and 6). Between the third and 
sixth passage, EHPCs were plated onto polyethyleneimine (PEI)-
coated coverslips, into 24-well plates; each well contained 
500 µl of either Neurobasal or DMEM/F12 differentiation media. 
Cells were given 24 hours to adhere to the PEI substrate; time 
0 of day 0 (the point at which the experimental time 
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officially was begun) was set as 24 hours after plating. 
Cells were incubated in the differentiation media for three 
days; at day 3 50% of the media was removed from each well and 
replaced with fresh differentiation media. Cells were 
returned to the incubator for a further 4 days. At day 7 the 
cells were removed from the incubator and processed for 
immunocytochemistry by the same procedure used for single-
label immunocytochemistry in Chapter 2. Cells were stained 
with antibodies against Nestin (neural stem cells), MAP2 
(neurons), GFAP (astrocytes), and RIP (oligodendrocytes) at 
concentrations identical to those used in Chapter 2. For each 
24-well plate, approximately five coverslips were allocated to 
staining with each antibody. Three replicates (three full 24-
well plates) were generated for both DMEM/F12 and Neurobasal 
media formulations. 
DMEM Mean DMEM SEM Neuro Mean Neuro SEM 
Nestin * 50.80 2.92 31.15 3.93 
MAP2 ** 12.78 2.95 69.64 3.30 
GFAP ** 68.96 2.32 17.59 1.34 
RIP 10.28 4.05 14.61 1. 70 
Table 1: Media comparison data. Data given are the mean and SEM of n=3 
experiments for each media type. DMEM = DMEM/F12 media; Neuro = 
Neurobasal media. Comparisons are made between DMEM mean and Neuro mean 
for each antibody using one-way ANOVA and Fisher's Protected LSD. * -
significant difference at P<.05; **=significant difference at P<.01. 
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As indicated in Table 1, significant differences were observed 
between cells differentiated in the DMEM/Fl2 and Neurobasal 
media. A significantly higher (P<.001) percentage of cells 
differentiated in DMEM/Fl2 media expressed the astrocytic 
marker GFAP (68.96% +/- 2.32%) than did cells in Neurobasal 
(17.59% +/- 1.34%). A significantly higher (P<.0159) 
percentage of cells in DMEM/Fl2 also expressed the stem cell 
marker Nestin (50.80% +/- 2.92%) than did cells in Neurobasal 
(31.15% +/- 3.93%). Conversely, a significantly lower 
(P<.0002) percentage of cells in DMEM/Fl2 expressed the 
neuronal marker MAP2 (12.78% +/- 2.95%) than did their 
counterparts in Neurobasal (69.64% +/- 3.30%). Percentage of 
cells expressing the oligodendrocyte marker RIP did not differ 
significantly between the two media groups; approximately 12% 
of cells expressed RIP in both groups. 
Our data indicate that the type of differentiation media 
used can exert a substantial effect on the expression of cell-
type specific markers. EHPCs in DMEM/Fl2 media appeared to 
differentiate predominantly into astrocytes (approximately 70% 
expressing GFAP), while EHPCs in Neurobasal media appeared to 
become largely neuronal (approximately 70% expressing MAP2). 
Because the primary goal of stem cell transplantation therapy 
is to replace neurons lost to degenerative disease processes, 
we selected the Neurobasal media to use for our further 
experiments, the results of which are reported in Chapter 2. 
